AlphaSituations-Event/Catalyst Driven Research, AlphaSituations

Robert Sassoon

AlphaSituations-Event/Catalyst Driven Research

AlphaSituations

Since its establishment, AlphaSituations has delivered a track record of outperformance with a hit rate of winners of more than 70% of its portfolio of ideas generating annualized average returns of 20%. In January 2022, AlphaSituations was contracted by Water Tower Research, an investor engagement and stakeholder communication platform to provide coverage of Special Situations

Event-Driven

Contingent value rights, or CVRs, are  arguably the rarest security class on a stock exchange, but have become more prevalent, particularly as part of the make-up in Biopharma merger transaction terms in the last few years. While these instruments do offer advantages to asset acquirers, we demonstrate below that CVR recipients rarely benefit.

Contingent value rights, or CVRs, are  arguably the rarest security class on a stock exchange, but have become more prevalent, particularly as part of the make-up in Biopharma merger transaction terms in the last few years. While these instruments do offer advantages to asset acquirers, we demonstrate below that CVR recipients rarely benefit.

MergerTalk: Contingency Value Rights - A Track Record Found Wanting

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Jacobio Pharmaceuticals / Equity Capital Markets

Recently, <a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1588148D CH)</a> got the approval to list on the main board of the Hong Kong Stock Exchange. Founded in 2015, Jacobio is committed to providing products and solutions to people’s health with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors. In China, Jacobio is the first to explore the KARS signaling pathway and is also the leading company in this field. Since the establishment more than five years ago, Jacobio has developed rapidly and steadily, and its pipeline is very distinctive. The following provides the insights on its pipeline.

Recently, Jacobio Pharmaceuticals (1588148D CH) got the approval to list on the main board of the Hong Kong Stock Exchange. Founded in 2015, Jacobio is committed to providing products and solutions to people’s health with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors. In China, Jacobio is the first to explore the KARS signaling pathway and is also the leading company in this field. Since the establishment more than five years ago, Jacobio has developed rapidly and steadily, and its pipeline is very distinctive. The following provides the insights on its pipeline.

Pre-IPO Jacobio Pharmaceuticals - Insights on Pipeline

Alpha-Centric ESG Research

Kyle Rudden

In <a href="https://www.smartkarma.com/insights/delisting-deceitful-chinese-companies-act-not-a-slam-dunk-and-has-more-bark-than-bite-if-it-passes" target="_blank" data-smartkarma-citation="insights:40025" rel="noopener">"Delisting Deceitful Chinese Companies Act" Not a Slam Dunk and Has More Bark Than Bite if It Passes</a>, I made three "predictions." First, the U.S. House of Representatives would not get around to voting on the "delisting act" before the end of the Congressional session. Second, if the House does vote, it would likely pass the bill. Third, if the bill passes, it would have more bark than bite.As a bloke called Meat Loaf once sung, "two out of three ain't bad."On Wednesday, the House voted and passed Senate Bill 945, titled the "Holding Foreign Companies Accountable Act." That the House managed to vote amidst the dual chaos of a raging pandemic and an unhinged President – so close to adjourning this 116th Congress – is a surprise. That it voted to pass S945 is not at all surprising, however, given widespread bi-partisan support for the bill.The real epiphany comes from additional details provided during House testimony just prior to the vote. Not many, but those details that were disclosed (plus the tone in which they were articulated) shed light on how S945 will be implemented and enforced by the SEC, and why foreign issuers and investors should duly-cautious but not overly-concerned. And why this "delisting bill" is ...... more bark than bite.This Insight presents an updated analysis of S945 (general and China/Hong Kong-specific aspects), shares new details provided by Representative Brad Sherman, offers an opinion on the SEC's likely approach to writing and enforcing S945 rules, analyses China/Hong Kong stocks most at risk under S945, and stocks affected by the France/Belgium angle (similar to China/Hong Kong).

In "Delisting Deceitful Chinese Companies Act" Not a Slam Dunk and Has More Bark Than Bite if It Passes, I made three "predictions." First, the U.S. House of Representatives would not get around to voting on the "delisting act" before the end of the Congressional session. Second, if the House does vote, it would likely pass the bill. Third, if the bill passes, it would have more bark than bite.As a bloke called Meat Loaf once sung, "two out of three ain't bad."On Wednesday, the House voted and passed Senate Bill 945, titled the "Holding Foreign Companies Accountable Act." That the House managed to vote amidst the dual chaos of a raging pandemic and an unhinged President – so close to adjourning this 116th Congress – is a surprise. That it voted to pass S945 is not at all surprising, however, given widespread bi-partisan support for the bill.The real epiphany comes from additional details provided during House testimony just prior to the vote. Not many, but those details that were disclosed (plus the tone in which they were articulated) shed light on how S945 will be implemented and enforced by the SEC, and why foreign issuers and investors should duly-cautious but not overly-concerned. And why this "delisting bill" is ...... more bark than bite.This Insight presents an updated analysis of S945 (general and China/Hong Kong-specific aspects), shares new details provided by Representative Brad Sherman, offers an opinion on the SEC's likely approach to writing and enforcing S945 rules, analyses China/Hong Kong stocks most at risk under S945, and stocks affected by the France/Belgium angle (similar to China/Hong Kong).

House Passes "Delisting Act" Giving SEC 90 Days to Write Its Rules (And Yes, More Bark Than Bite)

HBM Holdings Limited / Equity Capital Markets

On November 22nd 2020 , <a href="https://www.smartkarma.com/entities/harbour-biomed-holdings-limited" target="_blank" data-smartkarma-citation="entities:29717:1" rel="noopener">Harbour Biomed (2142 HK)</a> got approved to list on the main board of the Hong Kong Stock Exchange. Harbour is a biopharmaceutical company engaged in the R&amp;D of differential antibody therapies for immune and tumor diseases, and has more than 10 potential differentiated drug candidates in a diversified and balanced pipeline. So what is Harbour's core competence that set it apart from other biopharmaceutical companies?

On November 22nd 2020 , Harbour Biomed (2142 HK) got approved to list on the main board of the Hong Kong Stock Exchange. Harbour is a biopharmaceutical company engaged in the R&amp;D of differential antibody therapies for immune and tumor diseases, and has more than 10 potential differentiated drug candidates in a diversified and balanced pipeline. So what is Harbour's core competence that set it apart from other biopharmaceutical companies?

Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Jacobio Pharmaceuticals Group is a pre-revenue pharmaceutical company focused on “drugging the undruggable” targets to treat cancer. The company's pipeline is cutting edge and early stage, but comes with relatively high risk. A license and collaboration agreement with multinational <a href="https://www.smartkarma.com/entities/abbvie-inc" target="_blank" data-smartkarma-citation="entities:1135:1" rel="noopener">Abbvie Inc (ABBV US)</a> provides validation and non-dilutive funding. The management team is experienced and accomplished. The venture investors are credible; and the patent estate has a long life.This Insight provides an overview of the business, including some initial thoughts on valuation. We will provide an update with more definitive views on valuation in a future Insight.

Jacobio Pharmaceuticals Group is a pre-revenue pharmaceutical company focused on “drugging the undruggable” targets to treat cancer. The company's pipeline is cutting edge and early stage, but comes with relatively high risk. A license and collaboration agreement with multinational Abbvie Inc (ABBV US) provides validation and non-dilutive funding. The management team is experienced and accomplished. The venture investors are credible; and the patent estate has a long life.This Insight provides an overview of the business, including some initial thoughts on valuation. We will provide an update with more definitive views on valuation in a future Insight.

France

Sanofi operates as a pharmaceutical company. The Company manufactures prescription pharmaceuticals and vaccines. Sanofi also develops cardiovascular, thrombosis, metabolic disorder, central nervous system, and oncology medicines and drugs. Sanofi serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sanofi (SAN FP)

MergerTalk: Contingency Value Rights - A Track Record Found Wanting

CVRs have seen more usage in biopharma deals in the last few years, but is that a trend for investors to get excited about?

Robert Sassoon

Pre-IPO Jacobio Pharmaceuticals - Insights on Pipeline

This article analyzed the compelling and distinctive pipeline of Jacobio Pharmaceuticals in terms of projects. Meanwhile, it also disclose the...

Xinyao (Criss) Wang

House Passes "Delisting Act" Giving SEC 90 Days to Write Its Rules (And Yes, More Bark Than Bite)

The U.S. House of Representatives passed Senate Bill 945, the "Holding Foreign Companies Accountable Act." New details support the notion that S945...

Kyle Rudden

Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"

This article analyzed Harbour's core products, team, technology platforms, thoughts on valuation and the "hidden" value that is often easy to be...

Xinyao (Criss) Wang

Jacobio Pharma: Focus on Novel Targets

An in-depth overview of the proposed listing of Jacobio Pharmaceuticals using a framework that touches on the science, market opportunity,...

Kemp Dolliver, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)